Atlas Trials

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Clinical trial NCT03077828 · UNKNOWN

Trial details

NCT number
NCT03077828
Sponsor
Northwestern University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphocyte-Rich Classical Hodgkin LymphomaRecurrent Lymphocyte-Depleted Classical Hodgkin LymphomaRecurrent Mixed Cellularity Classical Hodgkin LymphomaRecurrent Nodular Sclerosis Classical Hodgkin LymphomaRefractory Lymphocyte-Depleted Classical Hodgkin LymphomaRefractory Mixed Cellularity Classical Hodgkin LymphomaRefractory Nodular Sclerosis Classical Hodgkin Lymphoma
Start date
2017-04-21
Primary completion
2020-12-30
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.